Byun Ja Min, Kim Daeyoon, Shin Dong-Yeop, Kim Inho, Koh Youngil, Yoon Sung-Soo
Department of Internal Medicine, Seoul Metropolitan Government Seoul National University Boramae Medical Center, Seoul, Republic of Korea
Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Hospital, Seoul, Republic of Korea.
In Vivo. 2019 Mar-Apr;33(2):611-619. doi: 10.21873/invivo.11518.
BACKGROUND/AIM: The aim of the study was to contribute to the development of adaptive risk stratification methods specific to Asian multiple myeloma (MM) patients undergoing autologous stem cell transplantation (ASCT).
We conducted this study to evaluate the prognostic impact of genetic abnormalities detected by fluorescent in situ hybridization (FISH) on survival outcomes in combination with the International Staging System (ISS) classification in 161 MM patients. This was a single-center retrospective longitudinal cohort study of newly diagnosed MM patients undergoing ASCT within 12 months from initial diagnosis. A single-center retrospective cohort study of newly diagnosed MM.
Patients were divided into 3 groups according to risk stratification: 1) low-risk, patients without del(17p13) nor t(14;16) or t(4;14) and ISS I/II; 2) high-risk, patients with t(4;14), regardless of ISS stage; 3) intermediate-risk, all remaining patients. The median PFS for the low-risk group was 18 months versus 13 months for the intermediate group (p=0.047, HR=1.527, 95%CI=1.006-2.316) versus 10 months for the high-risk group (p<0.001, HR=2.656, 95%CI=1.572-4.490).
An ISS/FISH-based prognostication strategy was developed that can predict PFS for Asian MM patients undergoing ASCT.
背景/目的：本研究旨在推动针对接受自体干细胞移植（ASCT）的亚洲多发性骨髓瘤（MM）患者的适应性风险分层方法的发展。
我们开展本研究，以评估荧光原位杂交（FISH）检测到的基因异常与国际分期系统（ISS）分类相结合对161例MM患者生存结局的预后影响。这是一项对初诊后12个月内接受ASCT的新诊断MM患者进行的单中心回顾性纵向队列研究。一项对新诊断MM患者的单中心回顾性队列研究。
根据风险分层，患者被分为3组：1）低风险组，无17p13缺失、无t(14;16)或t(4;14)且ISS I/II期的患者；2）高风险组，有t(4;14)的患者，无论ISS分期如何；3）中风险组，其余所有患者。低风险组的中位无进展生存期（PFS）为18个月，中风险组为13个月（p = 0.047，HR = 1.527，95%CI = 1.006 - 2.316），高风险组为10个月（p < 0.001，HR = 2.656，95%CI = 1.572 - 4.490）。
制定了一种基于ISS/FISH的预后策略，可预测接受ASCT的亚洲MM患者的PFS。
